Introduction
The risk of early death from coronary heart disease in heterozygotes for familial hypercholesterolaemia (FH) is well documented.'-4 There is, however, considerable variation in the age at which the first symptoms of ischaemic heart disease are noted or at which coronary death occurs. The reason for such variation may be associated with differences in serum cholesterol concentration5 or other risk factors such as blood pressure and smoking, or it may be associated with heterogeneity of the genetic mutations producing the clinical manifestation of FH.
Many clinicians have observed a specially favourable or poor prognosis for FH within families but few have had the opportunity to observe enough patients to verify this clinical impression. By combining two studies of families with FH, one from Norway and one from England, where the mortality rates from coronary heart disease in the general population are similar, we were able to investigate similarities within families in Department 
Patients and methods
The data from two family studies of patients with FH-one Norwegian with 139 kindreds and one British8 with 33 kindredswere combined. All index patients in the kindreds included in this analysis had tendinous xanthomata and hypercholesterolaemia. The cause of death in all patients contributing to these series was verified as being coronary heart disease from death certificates or hospital records.
Altogether 14 of the Norwegian kindreds and eight of the British kindreds contributed to these analyses of the sib-sib correlation coefficients. In addition 14 first cousin pairs were included from the Norwegian kindreds. The cumulative morbidity and mortality rates for the Norwegian and British series of heterozygotes for FH were remarkably similar. 4 Serum total cholesterol concentrations were determined by standard methods4 8 and adjusted for age and sex as described.
Statistical analysis-Intrafamilial correlations for age at death due to coronary heart disease were calculated for heterozygous sib pairs and cousins. Only relatives of the same generation were used in these calculations to reduce environmental differences which may have contributed to coronary risks. The significance of r values were tested after z transformation.9 The combined probabilities for correlation coefficients in sibs and cousins were obtained as recommended by Sverdrup'' with tables for small samples."
Results

AGE AT DEATH
The mean ages at death in the sibs of probands with FH who were used for the intrafamilial correlations are shown in table I. The difference in age at death between the Norwegian and British series was significant for men (P <0 001) but not for women. The age at death for women was converted to the equivalent value for men by subtracting nine years, which was the median difference in age at death in the larger Norwegian and British series of which these families were a subsample. The age at death of sibs of the British index patients with FH is shown in fig 1. More than one mode of distribution was clearly suggested in the British but not in the Norwegian series. The age at death from coronary heart disease in sib pairs is shown in fig 2. A trend for lower age at death in the British than in the Norwegian sibs was apparent.
An intrafamilial correlation for age at death in sibs was also apparent (fig 2) for each of the series as well as for the combined series. The computed results are given in 
Discussion
The age at which coronary heart disease proves fatal in patients with FH is likely to depend both on the severity of the effects of the dominant mutant gene and on the environmental and polygenic background against which the effect of the mutant gene is felt. If the genetic defect alone determined the course of the condition then all the heterozygotes for FH would be expected to die from coronary heart disease at a similar age. But this is clearly not the case. The prognosis is worse in men than in women,3 4and our observations show a range of age at death of 31 to 73 years in men and 41 to 93 years in women. It would be helpful to know some of the factors that contribute to differences in prognosis so that the maintenance of rigid diet and drug treatment could be encouraged in those in whom the outcome of the disease without treatment is likely to be most serious. The clinical impression that there are family similarities in the age at which heterozygotes for FH die from coronary heart disease is confirmed by our data, both in the combined series and from Norway and England separately. The combined influence of polygenic inheritance and environmental factors on age at death in heterozygotes for FH is difficult to evaluate. Most sibs in this series had not lived in the same household for at least 30 years before their death. The similarity of the correlation coefficients in sib pairs with that in cousins probably contradicts a large environmental influence. In general most interacting factors would decrease the correlation in sibs, not increase it. The correlation in age at death from coronary heart disease in patients with xanthomatosis was much higher than that observed for age at death due to other causes in the sibs without xanthomatosis.
No significant correlation was found between the age at death and the cholesterol concentration. This implies that the absolute increase in cholesterol or low density lipoprotein concentrations is of minor importance in the prognosis of heterozygotes for FH.
In 1941 Haldane pointed out that if a disease is determined by a single major gene with many modifying genes affecting the age of onset and, presumably, death and acting independently of each other then the sib-sib correlation will be about 0.5.12 If, however, the same clinical syndrome can be produced by several different gene mutations, each having its own narrow age range at onset or death, then the sib-sib correlation will be nearly 1 0. Any spread in the age at death due to polygenic or non-familial environmental modification will reduce the correlation. In 1947 Harris and Smith examined this concept more closely and concluded that, "If for any disease we obtain a parent-child correlation of about 0 5 or more, then we may suspect that there may be two or more genes mimicking one another; such a situation will probably show up by a multimodality in the distribution of ages of onset."'3 Biochemical heterogeneity has been suggested for autosomal dominantly inherited FH by Brown and Goldstein'4 and by Higgins et al,1'5 and biochemical heterogeneity of the gene mutation might also account for some differences in prognosis. We suggest that the observed intrafamilial correlation for the age at death from coronary heart disease in FH can be accounted for by at least two different gene mutations-each having its own expected age at death but subject to considerable variation by polygenic or environmental modification.
No further evidence for genetic heterogeneity was obtained for serum cholesterol concentrations. Linkage between FH and the C3 polymorphism has been reported'6-possibly similar to elliptocytosis and the Rh blood group, where linkage exists for one locus and not for the other. Analysis of the linkage data with respect to this is in progress.
Our findings have clinical implications. The patient's knowledge of his family history affects his attitude towards treatment, and those with families where early death among close relatives is the rule may be more compliant than those with a less tragic family history. As it is possible to diagnose FH early in life, decisions about treatment can be made early. Half the variation in age at death in sibs heterozygous for the FH gene(s) is accounted for by the observed correlation.
The biochemical findings of heterogeneity in FH have received some clinical support from our investigation. Further genetic work must be undertaken to elucidate the importance of genetic heterogeneity in FH, but at least some reassurance may be given to patients with FH where the family history is known to be good.
Summary
Patients with acute lymphoblastic leukaemia (ALL) were allocated at random either to stop maintenance chemotherapy after six 12-week courses or continue with a further six. The main difference between the two groups was in the incidence of bone-marrow relapse within nine months after stopping treatment. Such Introduction There is as yet no consensus on the optimum duration of treatment for acute lymphoblastic leukaemia (ALL), though three years has been most commonly used.' 2 A Medical Research Council trial (UKALL I) was designed to answer the question and we report here the results.
Plan of trial
Patients entered the trial from August 1970 to 31 December 1971. The trial protocol and preliminary data were reported previously,3
